A pharmaceutical company in New Jersey has voluntarily recalled thousands of bottles of a high blood pressure medication due to potential cross-contamination with another drug. The affected medication, Ziac, contains bisoprolol fumarate and hydrochlorothiazide tablets in 2.5 mg and 6.25 mg doses. The recall was initiated after testing revealed the presence of ezetimibe, a drug used for high cholesterol, in some batches. Despite the recall, the FDA classified it as a Class III recall, indicating that the risk of adverse health consequences is low. Glenmark Pharmaceuticals Inc., the manufacturer, is recalling the affected batches, which are identified by specific lot numbers and expiration dates ranging from November 2025 to May 2026. Consumers are advised to check the packaging for the affected product and return it to the place of purchase. This recall highlights the importance of stringent quality control measures in the pharmaceutical industry to ensure patient safety.
